Skendros et al. investigated the role of the NET/platelet/thrombin axis in ECs and demonstrated that complement inhibition has a therapeutic effect in SARS-CoV-2 infection, which is reflected by a decline in C-reactive protein and IL-6 levels, marked improvements in lung function, and the resolution of SARS-CoV-2-associated acute respiratory distress syndrome (ARDS) [47]. This evidence concerns the gene CRP and acute respiratory distress syndrome.